Tag: Formation Bio

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on...

Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch

Veteran pharma operator co-founded Ategenos to tackle the global $1 trillion crisis of medication non-adherence CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Ategenos, a pharmatech...

Formation Bio Announces First Class of Entrepreneurs in Residence to Drive Pipeline Growth and Strategic Partnerships

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsFormation Bio

Matter Bio Announces FDA Clearance of IND Application for LM-LLO-TT in Pancreatic Ductal Adenocarcinoma

PETER PIPER PIZZA IS THE ULTIMATE DESTINATION FOR SOCCER FANS THIS SUMMER

Power Metallic Mines Announces Closing of Brokered LIFE Offering for Gross Proceeds of C$28.2 Million and Welcomes Eric Sprott as a New Shareholder

Tag: Formation Bio

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch

Formation Bio Announces First Class of Entrepreneurs in Residence to Drive Pipeline Growth and Strategic Partnerships

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us